Image Provided By Pixabay
Pressure BioSciences, Inc (OTCQB: PBIO) has enjoyed a near record-breaking first half of 2021, reporting the second-highest revenue growth ever, driven by the company’s aggressive growth plan.
As Pressure BioSciences (PBI) works toward its goal of uplisting to NASDAQ or NYSE by the end of the year, its strong 2nd quarter results suggest that the company is well on its way toward achieving that goal. As PBI enters its 3rd quarter, here’s what it’s achieved so far and what investors can look forward to in the 2nd half of the year.
Strong Revenue Growth Driven by Expanding Client Base
PBI reported $608,900 in revenue for the 2nd quarter, bringing its total for the 1st half of 2021 to $1,168,800 — more than 124% higher than its revenue in the 1st half of 2020. While the bulk of that came from sales of its pressure-based instruments, the company saw growth across multiple revenue streams, including consumable sales and its BaroFold and Ultra Shear Technology (UST) services — 2 of the company’s highly regarded, pressure-based platforms that are expected to be top-performing revenue generators in 2022 and beyond.
The key to PBI’s strengthening financial position is the wide applicability of its revolutionary pressure-based technology. Rather than using temperature or chemicals to manipulate compounds in a scientific reaction (break down, extract, speed up or slow down reactions, inactivate, etc.), the company’s patented Ultra Shear Technology (UST) platform uses extremely high pressure with precise temperature control and high-intensity shearing to manipulate compounds in ways that have never really been done before.
The UST platform, for example, can create high quality, highly stable nanoemulsions of oil. Since oil-based ingredients are …